EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Active vitamin D analog and SARS ‐ CoV ‐2 IgG after BNT162b2 vaccination in patients with hemodialysis: Correspondence

Hinpetch Daungsupawong iD, Viroj Wiwanitkit iD

Therapeutic Apheresis and Dialysis · 2024

DOI: 10.1111/1744-9987.14171 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Therapeutic Apheresis and Dialysis, 2024. Verfasst von Hinpetch Daungsupawong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Private Academic Consultant, Phonhong, Lao People's Democratic Republic. Hauptthemen laut MEDLINE: Renal Dialysis, BNT162 Vaccine, COVID-19, SARS-CoV-2. Die Arbeit nennt 1 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We would like to share ideas on the publication. “Active vitamin D analog and severe acute respiratory syndrome coronavirus immunoglobulin G (SARS-CoV-2 IgG) after BNT162b2 vaccination in patients with hemodialysis” [1]. The purpose of the study was to look at the relationship between active vitamin D analogs and SARS-CoV-2 IgG levels in hemodialysis patients who had received the BNT162b2 (Pfizer©) coronavirus disease 2019 (COVID-19) vaccine. The usage of active vitamin D analog was linked, according to the results, to increased levels of SARS-CoV-2 IgG from the time of vaccination to 90 days afterward. Nearly two-thirds of the 418 participants in the study—whose mean age was 71.1 years—were administered active vitamin D analogs. This research concentrated on hemodialysis patients, a group recognized to be more vulnerable to severe COVID-19 consequences. Examining the relationship between SARS-CoV-2 IgG levels and the usage of active vitamin D analogs, the study shed light on possible vaccination-induced immune responses in this population. Blood samples were taken at various intervals prior to and during immunization, enabling a thorough examination of alterations in SARS-CoV-2 IgG levels in connection with the use of active vitamin D analogs. The findings imply that the use of active vitamin D analogs may be associated with increased SARS-CoV-2 IgG levels, which may have implications for hemodialysis patients' immunization plans. The absence of a control group in the study could be a possible issue. It is difficult to assess if the observed correlation between the use of active vitamin D analogs and increased SARS-CoV-2 IgG levels is actually a causal relationship in the absence of a comparison group of hemodialysis patients who did not get these supplements. Furthermore, other complicating factors such comorbidities or medication interactions that can affect SARS-CoV-2 IgG levels were not taken into consideration in this investigation. The study's dependence on self-reported medication use is another flaw. The study did not take drug adherence into consideration; it just looked at whether patients were prescribed active vitamin D analogs. The outcomes might have been impacted if the patients had not been taking their medication as directed. Furthermore, the study lacked details regarding the length and dosage of active vitamin D analog use, which may have an impact on the correlation between SARS-CoV-2 IgG levels and observed associations. Randomized controlled trials to examine the impact of active vitamin D analogs on SARS-CoV-2 IgG levels in hemodialysis patients may be one of the future approaches for this field of study. This would enable improved control over any confounding variables and offer stronger proof of causality. Furthermore, investigations may delve into the processes that underlie the correlation between active vitamin D analogs and SARS-CoV-2 IgG levels in order to gain a deeper comprehension of the potential impact of vitamin D on immunological responses to the COVID-19 vaccine. The authors declare no conflicts of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisBNT162 VaccineCOVID-19SARS-CoV-2Immunoglobulin GHumansMaleFemaleAgedAntibodies, ViralVitamin DMiddle AgedCOVID-19 VaccinesVaccination

Substanzen

BNT162 VaccineImmunoglobulin GAntibodies, ViralVitamin DCOVID-19 Vaccines

Autor:innen und Institutionen

  • Private Academic Consultant, Phonhong, Lao People's Democratic Republic.
  • Department of Research Analytics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences Saveetha University, Chennai, India.

ORCID-Profile: Hinpetch Daungsupawong, Viroj Wiwanitkit

Zitieren

APA

Daungsupawong, H., & Wiwanitkit, V. (2024). Active vitamin D analog and SARS ‐ CoV ‐2 IgG after BNT162b2 vaccination in patients with hemodialysis: Correspondence. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14171

Vancouver

Daungsupawong H, Wiwanitkit V. Active vitamin D analog and SARS ‐ CoV ‐2 IgG after BNT162b2 vaccination in patients with hemodialysis: Correspondence. Therapeutic Apheresis and Dialysis. 2024. doi:10.1111/1744-9987.14171

BibTeX
@article{Daungsupawong2024,
  author = {Daungsupawong, Hinpetch and Wiwanitkit, Viroj},
  title = {Active vitamin D analog and SARS ‐ CoV ‐2 IgG after BNT162b2 vaccination in patients with hemodialysis: Correspondence},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2024},
  doi = {10.1111/1744-9987.14171}
}
Kostenlos starten →